Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Aardvark Therapeutics, Inc. - Common Stock
(NQ:
AARD
)
4.900
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
226
Open
4.900
Bid (Size)
4.750 (300)
Ask (Size)
5.000 (300)
Prev. Close
4.900
Today's Range
4.900 - 4.900
52wk Range
4.740 - 17.94
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Monday's session: top gainers and losers
↗
March 02, 2026
Via
Chartmill
Performance
YTD
-62.9%
-62.9%
1 Month
-63.2%
-63.2%
3 Month
-47.1%
-47.1%
6 Month
-44.7%
-44.7%
1 Year
-61.5%
-61.5%
More News
Read More
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
March 02, 2026
Via
Chartmill
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial
↗
March 02, 2026
Via
Stocktwits
Get insights into the top gainers and losers of Monday's pre-market session.
↗
March 02, 2026
Via
Chartmill
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
February 28, 2026
From
The Schall Law Firm
Via
Business Wire
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts
↗
February 27, 2026
Via
Stocktwits
Top movers in Friday's after hours session
↗
February 27, 2026
Via
Chartmill
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
February 27, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Announces Leadership Appointments
February 12, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
February 12, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
February 10, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
December 10, 2025
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Let's take a look at the stocks that are in motion in today's session.
↗
December 03, 2025
Via
Chartmill
These stocks are moving in today's session
↗
December 03, 2025
Via
Chartmill
Which stocks are gapping on Wednesday?
↗
December 03, 2025
Via
Chartmill
Which stocks are moving after the closing bell on Tuesday?
↗
December 02, 2025
Via
Chartmill
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December
November 25, 2025
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
November 13, 2025
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
November 11, 2025
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
↗
November 07, 2025
Via
Benzinga
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
November 04, 2025
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 03, 2025
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November
November 03, 2025
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Aardvark Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aardvark Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aardvark Therapeutics, Inc. - Common Stock trade on?
Aardvark Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aardvark Therapeutics, Inc. - Common Stock?
The ticker symbol for Aardvark Therapeutics, Inc. - Common Stock is AARD on the Nasdaq Stock Market
What is the current price of Aardvark Therapeutics, Inc. - Common Stock?
The current price of Aardvark Therapeutics, Inc. - Common Stock is 4.900
When was Aardvark Therapeutics, Inc. - Common Stock last traded?
The last trade of Aardvark Therapeutics, Inc. - Common Stock was at 03/03/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.